 Lilly's CEO, Dave Ricks, has promised more early-stage deals to acquire new technologies, particularly in the areas of immunology. Morphic is developing a so-called selective oral small molecule inhibitor for the treatment of inflammatory bowel disease. That's an area that Lilly is already active in. And in terms of the share price action today...